| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LH | Common Stock | Sale | -$1.51M | -6.19K | -6.61% | $243.47 | 87.4K | Nov 11, 2024 | Direct | F1 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
On May 17, 2024, Labcorp Holdings Inc. ("LHI") became the successor of Laboratory Corporation of America Holdings ("LCAH") pursuant to LCAH's reorganization into a new holding company structure (the "Reorganization"). The Reorganization resulted in LHI becoming a parent holding company of LCAH but did not alter the proportionate interests of LCAH security holders.